Method and means for diagnosing autoimmune hepatitis using autoantibody markers

Abstract

The present invention relates generally to a method for determining or diagnosing the presence or absence, or the risk of development, or the therapy control of autoimmune hepatitis in a subject, in particular, in mammals. In addition, the present invention relates to test kits for use in the diagnosis or the determination of the presence or absence, or the risk of development or the therapy control of autoimmune hepatitis in a subject. In particular, the present invention relates to a method wherein the presence or absence of antibodies against the huntingtin interacting protein 1 related protein (HIP1 R) or against immunoreactive peptides derived therefrom are analyzed, the presence of said antibodies is indicative for the presence, or the risk of development or for therapy control of autoimmune hepatitis of said subject. Further, the present invention relates to the use of the HIP1 R or an immunoreactive peptide derived therefrom in the diagnosis, the risk assessment or therapy control of hepatitis diseases by determining the presence of antibodies, in particular, autoantibodies against said HIP1 R or immunoreactive peptide derived therefrom, this is particularly helpful for differential diagnosis of autoimmune hepatitis.

Dependencies are inferred from the claim text.